Home In vivo total antioxidant capacity: comparison of two different analytical methods
Article
Licensed
Unlicensed Requires Authentication

In vivo total antioxidant capacity: comparison of two different analytical methods

  • Cristina Vassalle , Silvano Masini , Clara Carpeggiani , Antonio L'Abbate , Claudio Boni and Gian CarloZucchelli
Published/Copyright: June 1, 2005

Abstract

Several methods to assess the total antioxidant capacity (TAC) are available. However, the final value of measured TAC in the sample depends on the procedure used in every specific assay. This makes crucial the comparison of different analytical methods. The aim of our study was to evaluate analytical characteristics and laboratory reliability of two different assays: the ferric-reducing ability (FRAP) assay and a new spectrophotometric test (OXY-adsorbent test, Diacron, Italy).

Unselected outpatients referred to the Institute of Clinical Physiology were studied (n=187, 58 females, 129 males, mean age: 65±13 years). All blood samples were maintained on ice, centrifuged within 15 minutes after blood collection and then stored at −80°C until performance of assay procedures.

OXY assay: The lower limit of sensitivity was 6 μmol HClO/ml. The assay was found to be linear up to 440 μmol HClO/ml (r=−0.99, p<0.001). Absorbance was linear over a wide concentration range with solutions containing uric acid in purified form (0–1000 μmol/l, r=−0.996, p<0.001), serum (r=−0.99, p<0.01) or plasma serially diluted (r=−0.99, p<0.01). Mean value in plasma samples accounted for 366.2±7.2 μmol HClO/ml. Mean OXY value in females (353.4±13.2 mmol HClO/ml) was not different from that detected in males (372±8.6 mmol HClO/ml). A significant difference was observed between subjects without and with hypertension in serum OXY levels (344.8±9.9 and 383.2±10 μmol HClO/ml, p<0.01, respectively).

FRAP assay: The lower limit of sensitivity was 15 μmol/l. Linearity was observed up to 1000 μmol/l (r=−0.998, p<0.001). Absorbance was linear over a wide concentration range with solutions containing uric acid in purified form (0–1000 μmol/l, r=0.997, p<0.001), serum (r=0.99, p<0.01) or plasma serially diluted (r=0.99, p<0.01). FRAP mean value in plasma samples, evaluated in 102 patients, accounted for 514.1±19.1 μmol/l. Mean FRAP in females (469±22.5 μmol/l) was not different from that detected in males (535±25.6 mmol/l).

FRAP vs. OXY: A significant direct relationship was observed when comparing FRAP with OXY levels in the whole population (r=0.22, p<0.05).

Neither of the methods are expensive and they are speedy and simple to perform. Values are reproducible and linearly correlated to the concentration of antioxidants present in the samples. For this reason, these methods may be considered practicable indicators of total antioxidant capacity, for routinely potential use in every laboratory and useful in all the studies concerning the evaluation of oxidative stress.

Published Online: 2005-6-1
Published in Print: 2004-2-16

Copyright © 2004 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. International collaboration in clinical chemistry and laboratory medicine: the Human Proteome Organization (HUPO) Plasma Proteome Project
  2. Current concepts in standardization of cardiac marker immunoassays
  3. Collagen, ageing and nutrition
  4. Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system-polymerase chain reaction
  5. High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy
  6. Limited usefulness of the PFA-100™ for the monitoring of ADP receptor antagonists–in vitro experience
  7. Isolation of plasma small-dense low-density lipoprotein using a simple air-driven ultracentrifuge and quantification using immunassay of apolipoprotein B
  8. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide
  9. Calcium oxalate crystallization in untreated urine, centrifuged and filtered urine and ultrafiltered urine
  10. Matrix effects in clinical immunoassays and the effect of preheating and cooling analytical samples
  11. Blood alcohol testing: comparison of the performance obtained with the different methods used in the Belgian external quality assessment schemes
  12. Determination of lipase catalytic activity in two reference materials: BCR 693 and BCR 694 by titrimetry at constant pH
  13. Evaluation of a new generation of plastic evacuated blood-collection tubes in clinical chemistry, therapeutic drug monitoring, hormone and trace metal analysis
  14. Association between the CYP2C9 polymorphism and the drug metabolism phenotype
  15. Analytical goals for coagulation tests based on biological variation
  16. In vivo total antioxidant capacity: comparison of two different analytical methods
  17. Performance evaluation of automated assays for β-CrossLaps, N-MID-Osteocalcin and intact parathyroidhormone (BIOROSE Multicenter Study)
  18. Evaluation of the blood gas analyzer GEM(r) PREMIER(tm) 3000
  19. Lactate dehydrogenase (LD) extra isoenzyme electrophoretic band between LD1 and LD2 caused by a complex with α1-lipoprotein. A case report
  20. Relationship between cryoglobulins and hepatitis C virus (HCV) core antigen or antibody titers
  21. Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter
  22. Biological variation of plasma chromogranin A
  23. Verification, validation and evaluation of analytical procedures in laboratory medicine
  24. DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): Consensus Paper on the Rational Clinical Use of Homocysteine, Folic Acid and B-Vitamins in Cardiovascular and Thrombotic Diseases: Guidelines and Recommendations
  25. Meetings and Awards
Downloaded on 14.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2004.016/html
Scroll to top button